Brolucizumab
- Generic Name
- Brolucizumab
- Brand Names
- Beovu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1531589-13-5
- Unique Ingredient Identifier
- XSZ53G39H5
- Background
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brolucizumab was granted FDA approval in October 2019.
- Indication
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 30
- Registration Number
- NCT05710471
- Locations
- 🇭🇰
Grantham Hospital, Hong Kong, Hong Kong
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9261
- Registration Number
- NCT05111743
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9456
- Registration Number
- NCT05082415
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9457
- Registration Number
- NCT05037396
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Berner Augenklinik
- Target Recruit Count
- 80
- Registration Number
- NCT04932980
- Locations
- 🇨🇭
Berner Augenklinik, Bern, Switzerland
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04774926
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT04764656
- Locations
- 🇵🇹
Novartis Investigative Site, Tomar, Portugal
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04697953
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Benha University
- Target Recruit Count
- 20
- Registration Number
- NCT04690062
- Locations
- 🇦🇪
INMC, Abu Dhabi, United Arab Emirates
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 494
- Registration Number
- NCT04662944
- Locations
- 🇪🇸
Novartis Investigative Site, Leon, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.